Prof. David Newby

Professor David Newby holds the prestigious British Heart Foundation (BHF) Chair of Cardiology at the University of Edinburgh, one of the most distinguished academic cardiology appointments in the United Kingdom. Based at the Royal Infirmary of Edinburgh, he has dedicated more than three decades to the diagnosis, treatment, and research of cardiovascular disease, particularly coronary artery disease and the technologies used to detect and manage it.

Prof. Newby is internationally celebrated for his leadership of the SCOT-HEART trial, a landmark randomised controlled study that fundamentally changed how coronary artery disease is diagnosed. The trial demonstrated that CT coronary angiography, when added to standard care for patients with stable chest pain, led to a significant reduction in fatal and non-fatal myocardial infarctions. Published in the New England Journal of Medicine and the Lancet, the SCOT-HEART results reshaped international clinical guidelines and are now embedded in the practice of cardiologists around the world.

As an interventional cardiologist, Prof. Newby routinely performs complex percutaneous coronary interventions including coronary angioplasty and stenting, as well as transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis who are at high or intermediate surgical risk. His clinical approach combines meticulous attention to procedural technique with a strong foundation in non-invasive imaging — he is a recognised authority on the use of cardiac CT in routine clinical practice.

Beyond the catheterisation laboratory, Prof. Newby is a gifted academic physician who mentors the next generation of cardiologists and cardiovascular scientists at Edinburgh. He leads a prolific research group within the BHF Centre of Research Excellence at Edinburgh and has attracted millions of pounds in competitive research funding. His ability to translate rigorous trial evidence into improved patient outcomes defines his contribution to British and global cardiology.

Prof. David Newby completed his undergraduate medical degree (MBChB) at the University of Edinburgh Medical School, establishing a lifelong academic relationship with one of Britain's most storied medical institutions. He subsequently pursued doctoral research, earning his MD and PhD degrees, both of which focused on cardiovascular physiology and the mechanisms of coronary disease — providing him with the scientific rigour that underpins his clinical and translational research.

His specialist training in cardiology took place across leading Scottish and English teaching hospitals, where he gained broad experience in general cardiology before subspecialising in interventional procedures and advanced cardiac imaging. He completed advanced fellowship training in interventional cardiology and subsequently undertook further training in cardiac CT and nuclear cardiology, recognising early the transformative role that imaging would play in cardiovascular medicine.

Prof. Newby holds Fellowship of the Royal College of Physicians of Edinburgh (FRCP), Fellowship of the European Society of Cardiology (FESC), and Fellowship of the American College of Cardiology (FACC). He was elected a Fellow of the Royal Society of Edinburgh — Scotland's national academy of science and letters — in recognition of his exceptional contribution to biomedical research. His academic appointment as BHF Chair reflects the highest level of sustained research achievement in British cardiovascular medicine.

Prof. Newby's clinical practice sits at the intersection of interventional cardiology and advanced cardiac imaging, giving him a uniquely comprehensive perspective on the management of coronary artery disease and structural heart conditions. His procedural portfolio includes coronary angioplasty, drug-eluting stent implantation, complex multivessel percutaneous coronary intervention (PCI), and transcatheter aortic valve replacement (TAVR/TAVI) for patients with severe aortic stenosis.

In imaging, Prof. Newby is a global authority on CT coronary angiography, having championed its adoption in clinical practice through his SCOT-HEART research. He routinely interprets coronary CT angiography studies, cardiac MRI, and nuclear cardiology scans, integrating multi-modality imaging findings into individualised treatment plans. He also has expertise in intravascular imaging techniques including intravascular ultrasound (IVUS) and optical coherence tomography (OCT), which allow precise assessment of coronary plaque and stent deployment.

Among the conditions he manages are stable and unstable coronary artery disease, acute coronary syndromes including ST-elevation myocardial infarction (STEMI), heart failure with reduced and preserved ejection fraction, aortic stenosis, and angina pectoris. Prof. Newby takes a holistic approach to secondary cardiovascular prevention, emphasising guideline-directed medical therapy, lifestyle intervention, and shared decision-making with his patients.

Prof. David Newby is one of the United Kingdom's most prolific cardiovascular clinical trialists. His flagship achievement is the SCOT-HEART trial (Scottish Computed Tomography of the HEART), which enrolled over 4,000 patients presenting with stable chest pain across seven Scottish centres. The five-year outcome data, published in the New England Journal of Medicine in 2018, showed a 41% reduction in fatal or non-fatal myocardial infarction in patients randomised to CT coronary angiography-guided management — a result that permanently altered international guidelines from the ESC, NICE, and ACC/AHA.

Prof. Newby also led the RESCUE trial, investigating the role of CT coronary angiography in emergency department chest pain pathways, and has been a chief or principal investigator on numerous BHF, NIHR, and European Research Council-funded studies. His research group at the BHF Centre of Research Excellence, Edinburgh has produced foundational work on coronary inflammation, vulnerable plaque imaging using 18F-NaF PET-CT, and the prognostic value of coronary calcium scoring.

He has authored or co-authored more than 300 peer-reviewed publications in journals including the New England Journal of Medicine, The Lancet, JACC, Circulation, and the European Heart Journal. He serves on editorial boards of major cardiology journals and is a regular invited speaker at ACC, ESC, and Heart congresses globally.

The Royal Infirmary of Edinburgh welcomes patients from across the world seeking expert cardiology care, and Prof. Newby's international reputation in coronary artery disease and cardiac imaging attracts referrals from Europe, the Middle East, North America, and beyond. International patients consulting with Prof. Newby benefit from access to the full diagnostic and interventional capabilities of the Royal Infirmary, including state-of-the-art cardiac catheterisation laboratories, dual-source CT scanners for coronary imaging, and a comprehensive cardiac rehabilitation programme.

Pre-consultation, patients can share prior imaging and investigation results for remote review, enabling efficient use of in-person appointment time. Prof. Newby's team coordinates closely with NHS Lothian's international patient services and with private cardiology providers at the Spire Murrayfield Hospital, Edinburgh, to offer flexible appointment options. Consultations are conducted in English, and the team can facilitate translation services as required. Follow-up care and communication with referring physicians internationally is handled through structured letters and telehealth consultations where appropriate.

Prof. David Newby has received numerous honours recognising his contributions to cardiovascular medicine and research. He was elected a Fellow of the Royal Society of Edinburgh, Scotland's national academy, placing him among an elite group of scholars recognised for outstanding intellectual contribution. He holds the British Heart Foundation Chair of Cardiology — one of only a small number of such endowed chairs in the UK — reflecting the BHF's confidence in his leadership of the cardiovascular research agenda.

His SCOT-HEART trial received the British Cardiovascular Society Award for best clinical research and was recognised internationally as among the most impactful cardiovascular trials of the 2010s. Prof. Newby has delivered named lectures at the European Society of Cardiology Congress and the American College of Cardiology Scientific Sessions. He is consistently listed among the most highly cited cardiovascular researchers in the United Kingdom.